Date: 2015-11-20
Type of information: Product acquisition
Compound: Abstral® (fentanyl) Sublingual Tablets
Company: Galena Biopharma (USA - OR) undisclosed private company
Therapeutic area: Cancer - Oncology
Type agreement: product acquisition
Action mechanism: Abstral® (fentanyl) Sublingual Tablets is approved by the FDA, and is a sublingual (under the tongue) fentanyl tablet for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain within minutes.
Disease: inadequately controlled breakthrough cancer pain
Details: * On November 20, 2015, Galena Biopharma announced the sale of its Abstral® (fentanyl) Sublingual Tablet product to a private company in a deal valued at up to $12 million, with $8 million cash upfront and up to $4 million in additional cash upon the achievement of certain sales milestones, effective as of November 19, 2015.
Mizuho Securities acted as exclusive advisor to Galena Biopharma on this transaction.
Financial terms:
Latest news:
